Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout
HealthcarePlatform
Neurocrine→Soleno Therapeutics
Apr 6, 2026

Channel-specific outreach playbooks for deal origination.
Comparison posts, methodology, and analysis from the Tentt team.
Monthly market reports on M&A and private equity activity.
Free calculators for M&A, lending, and deal analysis.
Origination in the Age of AI.
Tracking 1 M&A deal by Neurocrine.
Neurocrine→Soleno Therapeutics
Apr 6, 2026